Evergreen Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.28M Buy
5,107
+306
+6% +$143K 0.05% 296
2025
Q4
$2.18M Buy
4,801
+2,304
+92% +$993K 0.05% 293
2025
Q3
$978K Sell
2,497
-152
-6% -$63.5K 0.02% 412
2025
Q2
$1.18M Sell
2,649
-149
-5% -$68.7K 0.04% 334
2025
Q1
$1.36M Buy
2,798
+259
+10% +$121K 0.05% 292
2024
Q4
$1.02M Sell
2,539
-101
-4% -$46.8K 0.03% 332
2024
Q3
$1.23M Buy
2,640
+4
+0.2% +$1.92K 0.04% 307
2024
Q2
$1.24M Buy
2,636
+220
+9% +$95.5K 0.04% 284
2024
Q1
$1.01M Buy
2,416
+12
+0.5% +$5.07K 0.04% 292
2023
Q4
$978K Sell
2,404
-52
-2% -$19.2K 0.04% 297
2023
Q3
$854K Sell
2,456
-11
-0.4% -$3.85K 0.04% 304
2023
Q2
$868K Buy
2,467
+939
+61% +$316K 0.04% 306
2023
Q1
$481K Buy
1,528
+60
+4% +$18K 0.02% 383
2022
Q4
$424K Buy
1,468
+18
+1% +$5.49K 0.02% 400
2022
Q3
$420K Buy
1,450
+448
+45% +$129K 0.02% 372
2022
Q2
$283K Sell
1,002
-167
-14% -$44.7K 0.01% 436
2022
Q1
$305K Buy
1,169
+231
+25% +$54.8K 0.01% 478
2021
Q4
$206K Buy
+938
New +$182K 0.01% 591
2020
Q3
Sell
-741
Closed -$215K 441
2020
Q2
$215K Buy
+741
New +$201K 0.02% 351

Other funds holding VRTX

Evergreen Capital Management's VRTX Position: Q1 2026 in Review

Evergreen Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 6.4% in Q1 2026, buying an estimated $143K and bringing the position to 5,107 shares worth $2.28M. The position accounts for 0.05% of the portfolio, ranked #296.

Evergreen Capital Management first reported a position in VRTX in Q2 2020 and has held it in 19 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Evergreen Capital Management held 5,107 shares of Vertex Pharmaceuticals worth $2.28M as of Q1 2026.
  • Evergreen Capital Management bought 306 Vertex Pharmaceuticals shares in Q1 2026, an estimated $143K.
  • Vertex Pharmaceuticals made up 0.05% of Evergreen Capital Management's portfolio in Q1 2026, its #296 holding.
  • Evergreen Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 19 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Evergreen Capital Management's 13F filing for Q1 2026, filed 14 May 2026.